NZ337844A - 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds - Google Patents

6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds

Info

Publication number
NZ337844A
NZ337844A NZ337844A NZ33784498A NZ337844A NZ 337844 A NZ337844 A NZ 337844A NZ 337844 A NZ337844 A NZ 337844A NZ 33784498 A NZ33784498 A NZ 33784498A NZ 337844 A NZ337844 A NZ 337844A
Authority
NZ
New Zealand
Prior art keywords
amino
phenyl
pyrido
pyrimidine
methylphenyl
Prior art date
Application number
NZ337844A
Other languages
English (en)
Inventor
Shripad S Bhagwat
Chih-Hung Lee
Richard J Perner
Yu-Gui Gu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NZ337844A publication Critical patent/NZ337844A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ337844A 1997-04-16 1998-04-16 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds NZ337844A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83439397A 1997-04-16 1997-04-16
PCT/US1998/004127 WO1998046603A1 (en) 1997-04-16 1998-04-16 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
NZ337844A true NZ337844A (en) 2001-11-30

Family

ID=25266829

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ337844A NZ337844A (en) 1997-04-16 1998-04-16 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds

Country Status (20)

Country Link
EP (1) EP0979230A1 (es)
JP (1) JP2001520649A (es)
KR (1) KR20010006453A (es)
CN (1) CN1259948A (es)
AR (1) AR012435A1 (es)
AU (1) AU744528B2 (es)
BG (1) BG103861A (es)
BR (1) BR9809088A (es)
CA (1) CA2287465A1 (es)
CO (1) CO4940439A1 (es)
HU (1) HUP0001402A3 (es)
IL (1) IL131892A0 (es)
NO (1) NO995033L (es)
NZ (1) NZ337844A (es)
PL (1) PL336262A1 (es)
SK (1) SK142099A3 (es)
TR (1) TR199902456T2 (es)
TW (1) TW458977B (es)
WO (1) WO1998046603A1 (es)
ZA (1) ZA982912B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
PL366918A1 (en) * 2001-02-12 2005-02-07 F.Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
KR20070086076A (ko) 2004-11-12 2007-08-27 트러스티즈 오브 터프츠 칼리지 리파아제 억제제
EP2139332A4 (en) * 2007-03-28 2010-04-21 Merck Sharp & Dohme SUBSTITUTED PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
BR112015007182A2 (pt) * 2012-10-05 2017-07-04 Rigel Pharmaceuticals Inc inibidores de gdf-8
WO2017205848A1 (en) * 2016-05-27 2017-11-30 Legacy Emanuel Hospital & Health Center Methanocarba derivatives of pseudoribose that inhibit adenosine kinase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
TW458977B (en) 2001-10-11
KR20010006453A (ko) 2001-01-26
AU744528B2 (en) 2002-02-28
PL336262A1 (en) 2000-06-19
ZA982912B (en) 1998-10-09
BG103861A (en) 2000-06-30
AR012435A1 (es) 2000-10-18
EP0979230A1 (en) 2000-02-16
TR199902456T2 (xx) 2000-07-21
BR9809088A (pt) 2000-08-01
CN1259948A (zh) 2000-07-12
NO995033D0 (no) 1999-10-15
SK142099A3 (en) 2000-05-16
CO4940439A1 (es) 2000-07-24
JP2001520649A (ja) 2001-10-30
NO995033L (no) 1999-12-15
HUP0001402A2 (hu) 2000-10-28
IL131892A0 (en) 2001-03-19
CA2287465A1 (en) 1998-10-22
HUP0001402A3 (en) 2001-01-29
AU7098198A (en) 1998-11-11
WO1998046603A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
WO2018121228A1 (zh) 一种具有axl抑制活性的化合物及其制备和应用
KR20080080584A (ko) ｃ-Ｍｅｔ의 억제제 및 이의 용도
KR101561756B1 (ko) 이미다조 피라진
KR20090018895A (ko) 야누스 키나제의 억제제로서 유용한 데아자푸린
SK17992000A3 (sk) Premostené indenopyrolokarbazoly
EP3952874A1 (en) Selective inhibitors of protein arginine methyltransferase 5
WO1998046605A1 (en) 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors
WO2005058315A1 (en) Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
NZ337844A (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
WO2001057040A1 (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6030969A (en) 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
AU741033B2 (en) 5,6,7-trisubstituted-4-aminopyridol(2,3-d)pyrimidine compounds
US20090143375A1 (en) Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents
JP2005509641A (ja) 新規ヒドロキシアルキルインドロカルバゾール化合物、その調製方法、およびそれらを含む医薬組成物
CN112250666B (zh) 取代的嘧啶类化合物及其用途
CZ360199A3 (cs) Sloučeniny 6,7-disubstituovaného-4- aminopyrido [2,3-dJ pyrimidinu
CZ350899A3 (cs) 5,6,7-trisubstituované-4-aminopyrido-[2,3- D]pyrimidinové sloučeniny
MXPA99009512A (es) Compuestos de 4-aminopirido(2,3-d)pirimidina 5,6,7-trisubstituidos
AU2019344041A1 (en) Cdc7-inhibiting purine derivatives and their use for the treatment of neurological conditions
CN117343081A (zh) Mat2a抑制剂、药物组合物及其用途
CZ339399A3 (cs) 5,7-Disubstituované 4-aminopyrido[2.3- D]pyrimidinové sloučeniny a jejich použití jako inhibitorů adenosin kinasy
EP1395267A2 (en) Therapeutic compositions for modulating the immune response in a mammal and use thereof

Legal Events

Date Code Title Description
PSEA Patent sealed